Rosacea is a chronic inflammatory dermatosis, which globally affects 1 to 22% of the world’s population, with higher percentages seen in western countries.1-4
There are four internationally recognised subtypes: erythematotelangiectatic (ETR), phymatous (PR), papulopustular (PPR) and ocular (OR).5
Patients do not?clinically progress through subtypes, but may have symptoms?that fit into multiple subtypes. Some of the signs and symptoms?can include: papules, pustules, erythema, flushing, telangiectasia, oedema, plaque formation, rhinophyma or ocular involvement, or a combination of the above.1,6,7
These symptoms can be transient or persistent and can progress in severity. Although rosacea is a benign condition, it can cause significant psychosocial distress, leading to?a decreased quality of life (QoL) and mental health conditions.
For instance, a study surveying more than 400 patients indicated that 75% had low self-esteem9,10 and an American survey conducted between 1995-2002, with 13.9 million rosacea patients, suggested 65%…
